![](https://netrf.org/wp-content/uploads/2018/05/AAA-book-6x9-FINAL-2018-03-30_Page_01-300x200.jpg)
Lessons of NET Cancer
PRRT Patients Tell Their Stories Following the early 2018 FDA approval of the first Peptide Receptor Radionuclide Therapy (PRRT) using lutetium Lu-177 dotatate, many people are
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $37.6 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $37.6 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
PRRT Patients Tell Their Stories Following the early 2018 FDA approval of the first Peptide Receptor Radionuclide Therapy (PRRT) using lutetium Lu-177 dotatate, many people are
The first step in curing a disease is understanding it. Unfortunately, there is a lot we still don’t know about small-intestinal NETs (SI-NETs). That’s why
by Ronny Allan, NET Patient Activist Doctors and scientists are always looking for better ways to care for patients with cancer; they are looking for
[breakout] Talk to your doctor before changing your activity level. You may need to make important modifications based on medication you are taking, surgery you
A Journey in Advocacy Greta Stifel isn’t just “rare,” she’s triple “rare.” After being diagnosed with Carcinoid Cancer, she simultaneously developed Carcinoid Syndrome, and recently
New treatment for GI and pancreatic NETs The U.S. Food and Drug Administration (FDA) has approved Peptide Receptor Radionuclide Therapy (PRRT) with a new radiopharmaceutical for
Much about a carcinoid cancer cell remains a mystery. For that reason, NETRF funds research to understand how and why a neuroendocrine cancer cell comes
NETRF in collaboration with NANETS awarded the 2017 Basic Translational Science Investigator grant to Brian R. Untch, M.D., at Memorial Sloan Kettering Cancer Center for his proposal, “Enhancing Peptide Receptor Radionuclide Therapy in Well-Differentiated Pancreatic Neuroendocrine Tumors.”
Peptide Receptor Radionuclide Therapy (PRRT) treats neuroendocrine tumors (NETs) by converting a cancer cell’s unique characteristics into a welcome mat for a Trojan Horse packed with cancer-killing radiation.
He is a pioneer whose work has helped extend the horizon of cancer care, creating a new category of individualized immunotherapy. Carl June, MD, has conducted 25 years of scientific research to advance CAR T-cell therapy. And all that knowledge is now helping to tackle NETs.